Diabetes mellitus and its treatment

International Journal of Diabetes and Metabolism

Volumn 13, Issue 3, 2005, Pages 111-134

  Bastaki, Salim ^a  

^a UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Diabetes mellitus; Insulin; Oral hypoglycaemic agents; Treatment

Indexed keywords

ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; ALPHA INTERFERON; ANTIDIABETIC AGENT; BIGUANIDE DERIVATIVE; BUFORMIN; CARBUTAMIDE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLISOLAMIDE; GLISOXEPIDE; GLUCOCORTICOID; GLYCYCLAMIDE; HERBACEOUS AGENT; INSULIN; INSULIN LISPRO; MEGLITINIDE; METFORMIN; NICOTINIC ACID; PENTAMIDINE; PHENFORMIN; SULFONYLUREA DERIVATIVE; THIAZOLE; THIAZOLIDENEDIONE DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; AGRANULOCYTOSIS; ANOREXIA; APLASTIC ANEMIA; BLOATING; BLOOD VESSEL INJURY; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CHRONIC DISEASE; CIGARETTE SMOKING; CLINICAL FEATURE; CLINICAL TRIAL; DIABETIC NEPHROPATHY; DIABETIC NEUROPATHY; DIABETIC RETINOPATHY; DIARRHEA; DIET RESTRICTION; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG MECHANISM; EDEMA; EXERCISE; FEVER; FLATULENCE; GASTROINTESTINAL DISEASE; GENETIC HETEROGENEITY; GLYCEMIC CONTROL; GLYCEMIC INDEX; HEADACHE; HEMOLYTIC ANEMIA; HUMAN; HYPERGLYCEMIA; HYPERSENSITIVITY REACTION; HYPOGLYCEMIA; INSULIN ALLERGY; INSULIN DEFICIENCY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; JAUNDICE; LACTIC ACIDOSIS; LIFESTYLE; LIPOATROPHY; LIPOHYPERTROPHY; LIVER INJURY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PREGNANCY DIABETES MELLITUS; PRESCRIPTION; PROPHYLAXIS; PROTEIN INTAKE; PROTEIN METABOLISM; PRURITUS; RASH; REVIEW; RISK FACTOR; SIDE EFFECT; SUSTAINED RELEASE PREPARATION; TASTE DISORDER; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; ULCER; URTICARIA; WEIGHT REDUCTION;

EID: 33751249006     PISSN: 16067754     EISSN: None     Source Type: Journal    
DOI: 10.1159/000497580     Document Type: Review

References (227)

1. Kumar PJ, Clark M. Textbook of Clinical Medicine. Pub: Saunders (London), pp 1099-1121, 2002.
2. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
3. Beverley B, Eschwège E. The diagnosis and classification of diabetes and impaired glucose tolerance. In: Textbook of Diabetes 1 Ed: John C Pickup and Gareth Williams Third edition; Chapter 2, pp 2.1-2.11, 2003.
4. Lindberg G, Lindblad U, Melander A. Sulfonylureas for treating type 2 diabetes mellitus. Cochrane Database Systemic Reviews volume 3, 2004.
5. Bearse MA Jr, Han T, Schneck ME, et al. Local multifocal oscillatory potential abnormalities in diabetes and early diabetic retinopathy. Invest Ophthal Vis Sci 2004; 45: 3259-3265.
6. Hove MN, Kristensen JK, Lauritzen T, Bek T. The prevalence of retinopathy in an unselected population of type 2 diabetes patients from Arhus County, Denmark. Acta Ophthalmol Scand 2004; 82: 443-448.
7. Seki M, Tanaka T, Nawa H, et al. Involvement of brain-derived neurotrophic factor in early retinal neuropathy of streptozotocin-induced diabetes in rats: therapeutic potential of brain-derived neurotrophic factors for dopaminergic amacrine cells. Diabetes 2004; 53: 2412-2419.
8. Moran A, Palmas W, Field L, et al. Cardiovascular autonomic neuropathy is associated with microalbuminuria in older patients with type 2 diabetes. Diabetes care 2004; 27: 972-977.
9. Huang C, Kim Y, Caramori ML, et al. Cellular basis of diabetic nephropathy: II. The transforming growth factor-beta system and diabetic nephropathy lesions in type 1 diabetes. Diabetes 2002; 51: 3577-3581.
10. Shukla N, Angelini GD, Jeremy JY, et al. Homocysteine as a risk factor for nephropathy and retinopathy in type 2 diabetes. Diabetologia 2003; 46; 766-772.
11. Svensson M, Eriksson JW, Dahlquist G. Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care 2004; 27: 955-962.
12. Saely CH, Aczel S, Marte T, et al. Cardiovascular complications in type 2 diabetes mellitus depend on the coronary angiographic state rather than on the diabetes state. Diabetologia 2004; 47: 145-146.
13. Wallace C, Reiber GE, LeMaster J, et al. Incidence of falls, risk factors for falls, and fall-related factures in individuals with diabetes and a prior foot ulcer. Diabetes Care 2002; 25: 1983-1986.
14. Centers for Disease Control and Prevention (CDCP). History of foot ulcer among persons with diabetes - Unites States, 2000-2002. Morbidity & Mortality Weekly Report. 2003; 52: 1098-1102.
15. Amos A, McCarty D, Zimmet P. The rising global burden of diabetes and its complications, estimates and projections to the year 2010. Diabetic Med 1997; 14: S1-S85.
16. King H, Aubert R, Herman W. Global burden of diabetes, 1995-2025. Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431.
17. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the Doomsday scenario be averted? J Med 2000; 247: 301-310.
18. World Health Organization Expert Committee on Diabetes Mellitus. Second WHO Technical Report, Series 310. Geneva: World Health Organization, 1965.
19. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 18: 1039-1057.
20. World Health Organization Expert Committee on Diabetes Mellitus. Second WHO Technical Report, Series 646. Geneva: World Health Organization 1980.
21. World Health Organization Study Group. Diabetes Mellitus: WHO Technical Report, Series 727. Geneva: World Health Organization, 1985.
22. World Health Organization Consultation. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications, Part 1: Diagnosis and classification of Diabetes Mellitus. Report of a WHO Consultation. Geneva: World Health Organization, 1999.
23. rd Ed., pg 3-14, 2004.
24. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med 1994; 331: 1428-1436.
25. Betterle C, Zannette F, Pedini B, et al. Clinical and subclinical organ-specific autoimmune manifestations in type 1 (insulin-dependent) diabetic patients and their first-degree relatives. Diabetologia 1983; 26: 431-436.
26. McLarty DG, Athaide I, Bottazzo GF, et al. Islet cell antibodies are not specifically associated with insulin-dependent diabetes in rural Tanzanian Africans. Diabetes Res Clin Pract 1990; 9: 219-224.
27. Ahrén B, Corrigan CB. Intermittent need for insulin in a subgroup of diabetic patients in Tanzania. Diabet Med 1984; 2: 262-264.
28. nd edn. Chichester: Wiley, 1997; pp 635-712.
29. Report of World Health Organization Study Group. WHO Technical Report Series 1994; World Health Organization, 844: Geneva, Prevention of Diabetes Mellitus.
30. Harris MI, Flegal KM, Cowie CC, Eberhardt MS, Goldstein DE, Little RR, Wiedmeyer HM, Byrd-Holt DD. Prevalence of diabetes, impaired fasting glucose, and impaired glucose tolerance in U.S. adults: the third National Health and Nutritional Examination Survey, 1988-1994. Diabetes Care, 1998; 21: 518-524.
31. Zimmet P. Type 2 (non-insulin-dependent) diabetes: an epidemiological overview. Diabetologia 1982; 22: 399-411.
32. Christacopoulos PD, Karamanos BG, Tountas CD, et al. The prevalence of diabetes mellitus and non-diabetic glycosuria in a rural population in Greece. Diabetologia 1975; 11: A-335.
33. Bloomgarden ZT. American Diabetes Association annual meeting 1996: the etiology of type II diabetes, obesity, and the treatment of type II diabetes. [Congresses] Diabetes Care. 1996; 19: 1311-1315.
34. Sekikawa A, Tominaga M, Takahashi K, et al. Prevalence of diabetes and impaired glucose tolerance in Funagata area in Japan. Diabetes Care 1993; 16: 57-574.
35. Ramachandran A, Snehelatha C, Latha E, et al. Rising prevalence of NIDDM in an urban population in India. Diabetologia 1997; 40: 232-237.
36. Zimmet P, Dowse G, Finch C, Serjeantson S, King H. The epidemiology and natural history of NIDDM - lessons from the South Pacific. Diabetes Metab Rev 1990; 6: 91-124.
37. Eriksson J, Saloranta C, Widen E, et al. Non-esterified fatty acids do not contribute to insulin resistance in persons at increased risk of developing type 2 (non-insulin-dependent) diabetes mellitus. [Journal Article] Diabetologia. 1991; 34: 192-197.
38. Glaser NS. Non-insulin-dependent diabetes mellitus in childhood and adolescence. Pediatr Clin North Am 1997; 44: 307-337
39. Scott CR, Smith JM, Pihoker C. Characteristics of youth-onset non-insulin-dependent diabetes mellitus and insulin-dependent diabetes mellitus at diagnosis. Pediatr 1997; 100: 84-91.
40. Cockram CS. Diabetes mellitus: perspective from the Asia-Pacific region. Diab Res Clin Pract 2000; 50 (suppl 2): S3-S7.
41. Zimmet P, Alberti KGMM, Shaw T. Global and Social implications of diabetes epidemic. Nature 2001; 414: 782-787.
42. Miller CD, Phillips LS, Ziemer DC, et al. Hypoglycaemia in patients with type 2 diabetes mellitus. Arch Intern Med; 2001; 161: 1653-1659.
43. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2001; 24 (suppl 1): S77-S79.
44. th ed. Stamford, CT, Appleton & Lange, 1997; 401-454.
45. American Diabetes Association. Gestational diabetes mellitus. Diabetes Care 2001; 24 (suppl 1): S5-S19.
46. Pandit Mk, Burke J, Gustafson AB. Drag-induced disorders of glucose tolerance. Ann Intern Med 1993; 118: 529-539.
47. Froguel P, Vaxillaire M, Sun F, et al. Close linkage of glucokinase locus on chromosomes 7p to early-onset non-insulin-dependent diabetes mellitus. Nature 1992; 356: 162-164.
48. Bell GI, Xiang KS, Newman MV, et al. Gene for non-insulin-dependent diabetes mellitus (maturity-onset diabetes of the young subtype) is linked to DNA polymorphism on human chromosome 20q. Proc Natl Acad Sci USA 1991; 88: 1484-1488.
49. Vaxillaire M, Boccio V, Philippi A, et al. A gene for maturity onset diabetes of the young (MODY) maps to chromosome 12q. Nature Genet 1995; 9: 418-423.
50. Stoffers DA, Ferrer J, Clarke WL, Habener JF. Early-onset type-II diabetes mellitus (MODY) linked to IPF-1. Nature Genet 1997; 17: 138-139.
51. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nature Genet 1997; 17: 384-385.
52. Malecki MT, Jhala US, Anatonellis A, et al. Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nature Genet 1999; 23: 323-328.
53. Lederman HM. Is maturity onset diabetes at young age (MODY) more common in Europe than previously assumed? Lancet 1995; 345: 648.
54. O'Dea K. Marked improvement in carbohydrate and lipid metabolism in diabetic Australian Aborigines after temporary reversion to traditional lifestyle. Diabetes 1984; 33: 596-603.
55. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetic Care 1997; 20: 537-544.
56. Eriksson KF, Lindgarde F. Prevention of type 2 (Non-insulin-dependent) diabetes mellitus by diet and physical exercise: 6-year Malmo feasibility study. Diabetologia 1991; 34: 891-898.
57. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incident of type 2 diabetes with lifestyle intervention or metformin. N Eng J Med 2002; 346: 393-403.
58. Watkins PJ, Drury PL, Taylor KW. An Overview of management. In: diabetes and its Management. ED Blackwell Scientific Publication; fourth edition, 1990, pp 63-66.
59. nd edn. Bethesda, MD: National Institutes of Health, 1995. (NIH Publication no. 95-1468.)
60. Ross R, Dagnone D, Jones PJ, et al. Reduction in obesity and related co-morbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Int Med 2000; 133: 92-103.
61. Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS Jr. Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. [Journal Article] N Eng J Med 1991; 325: 147-152.
62. Manson JE, Nathan DM, Krolewski AS et al. A prospective study of exercise and incidence of diabetes among U.S. male physicians. J Am Med Assoc 1992; 268: 63-67.
63. Felig P, Cherif A, Minagawa A, Wahren J. Hypoglycaemia during prolonged exercise in normal men. N Eng J Med 1982; 306: 895-900.
64. Calles J, Cunningham JJ, Nelson L, et al. Glucose turnover during prolonged intensive exercise. Diabetes 1983; 32: 734-738.
65. Kjaer M, Farrell PA, Christensen NJ, Galbo H. Increase epinephrine response and inaccurate glucoregulation in exercising athletes. J Appl Physiol 1986; 61: 1693-1700.
66. Moy CS, Songer TJ, LaPorte RE, et al. Insulin-dependent diabetes mellitus, physical activity and death. Am J Epidemiol 1993; 137: 74-81.
67. Goldstein DJ. Beneficial health effects of modest weight loss. Int J Obes 1992; 16: 397-415.
68. Diabetes and Nutrition Study Group of the European Association for the Study of Diabetes. Recommendations for the nutritional management of patients with diabetes mellitus. Eur J Clin Nutr 2000; 54: 353-355.
69. Mensink RP, Katan MB. Effects of dietary trans fatty acids on high-density lipoprotein cholesterol levels in healthy subjects. N Eng J Med 1990; 323: 439-445.
70. Zock PI, Katan MB. Hydrogenation alternatives: effects of trans fatty acids and stearic acid versus linoleic acid on serum lipids and lipoprotein in humans. J Lipid Res 1992; 33: 399-410.
71. Mensink RP, Zock PL, Katan MB, Hornstra G. Effect of dietary cis and trans fatty acids on serum lipoprotein (a) levels in humans. L lipid Res 1992; 33: 1493-1501.
72. Foley M, Ball M, Chisholm A, et al. Should mono- or polyunsaturated fats replace saturated fat in the diet? Eur J Clin Nutr 1992; 46: 429-436.
73. Popp-Snijders C, Schouten JA, Heine RJ, et al. Dietary supplementation of omega-3 polyunsaturated fatty acids improve insulin sensitivity in non-insulin dependent diabetes. Diabetes Res 1987; 4: 141-147.
74. Mori TA, Vandongen R, Masarei JR, et al. Dietary fish oil increases serum lipids in insulin-dependent diabetes compared with healthy controls. Metabolism 1989; 38: 404-409.
75. Parillo M, Rivellese AA, Ciardullo AV, et al. A high-monounsaturated-fat/ low-carbohydrate diet improves peripheral insulin sensitivity in non-insulin dependent diabetic patient. Metabolism 1992; 41: 1373-1378.
76. Hu FB and Manson JE. Management of diabetes: diet and lifestyle modification. In: Textbook of Diabetes Vol. 1 Ed. John C Pickup & Gareth Williams 2003 pp 36.1-36.13.
77. Mann JI and Lewis-Barned NJ. Dietary management of diabetes mellitus in Europe and North America. In: International Textbook of Diabetes Mellitus third ed. Vol. 1 Ed. RA Defronzo, E Ferrannini, H Keen, P Zimmet, 2004, pp725-739.
78. Mann JI. Diet and diabetes. Diabetologia 1980; 18: 89-95.
79. Jenkins DJA, Wolever TM, Taylor RH, et al. Glycaemic index of foods: a physiological basis for carbohydrate exchange. Am J Clin Nutr 1981; 34: 362-366.
80. Brand-Miller J, Wolever TMS, Colagirui S, Foster-Powell K. The glucose revolution: the authoritative guide to the Glycaemic Index. New York: Marlowe, 1999.
81. Jenkins DJA, Leeds AR, Gassull MA, et al. Decrease in postprandial insulin and glucose concentrations for guar and pectin. Ann Intern Med 1977; 86: 20-23.
82. Aro A, Uusitupa M, Voutilainen E, et al. Improved diabetic control and hypocholesterolaemia effect induced by long-term supplementation with guar in type 2 diabetics. Diabetologia 1981; 21: 29-33.
83. Salmeron J, Manson JE, Stampfer MJ, et al. Dietary fiber, glycaemic load, and risk of non-insulin-dependent diabetes mellitus in women. JAMA 1997; 277: 472-477.
84. Hu FB, van Dam RM, Liu S. Diet and risk of type II diabetes: the role of types of fat and carbohydrate. Diabetologia 2001; 44: 805-817.
85. Liu S, Manson JE, Stampfer MJ, et al. Dietary glycaemic load assessed by food frequency questionnaire in relation to plasma high-density lipoprotein cholesterol and fasting triglycerides in postmenopausal women. Am J Clin Nutr 2001; 73: 560-566.
86. Peterson DB, Lambert J, Gerring S, et al. Sucrose in the diet of diabetic patients-just another carbohydrate? Diabetologia 1986; 29: 216-220.
87. Born P, Eimiller A, Paul F. High rate of gastrointestinal side effects in fructose-consuming patients. Diabetes Care 1987; 10: 376-377.
88. Keller K, Whittaker E, Sullivan L, et al. Effect of restricting dietary protein on the progression of renal failure in patients with insulin-dependent diabetes mellitus. N Eng J Med 1991; 324: 78-84.
89. Jones SL, Kontessis P, Wiseman M, et al. Protein intake and blood glucose as modulators of glomorular filtration rate (GFR) in hyperfiltering diabetic patients. Kidney hit 1992; 41: 1620-1628.
90. Pomerleau J, Verdy M, Garrel DR, Nadeau MH. Effect of protein intake on glycaemic control and renal function in type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 829-834.
91. Brodsky IG, Robbins DC, Hiser E, et al. Effect of low-protein diets on protein metabolism in insulin-dependent diabetes mellitus patients with early nephropathy. J Clin Endocrinol Metab 1992; 75: 351-357.
92. Jibani MM, Bloodworth LL, Foden E, et al. Predominately vegetarian diet in patients with incipient and early clinical diabetic nephropathy: effects on albumin excretion rate and nutritional status. Diabet Med 1991; 8: 949-953.
93. Walter RM, Uriu-Hare JY, Lewis Olin K, et al. Copper, zinc, manganese, and magnesium status and complications of diabetes mellitus. Diabetes Care 1991; 14: 1050-1056.
94. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26 (suppl 1): S80-S82.
95. Paolisso G, D'Amore A, Galzerano D, Balbi V, et al. Daily vitamin E supplements improve metabolic control but not insulin secretion in elderly type 2 diabetic patients. Diabetes Care 1993; 16: 1433-1437.
96. Rimm EB, Willett W, Hu FB, et al. Folate and vitamin B6 form diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998; 279: 359-365.
97. Munshi MN, Stone A, Fink L, Foneca V. Hypercysteinaemia following methionine load in patients with non-insulin-dependent diabetes mellitus and macrovascular disease. Metabolism 1996; 45: 133-135.
98. Rimm E, Williams P, Fosher K, Criqui M, Stampfer MJ. Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 1999; 319: 1523-1528.
99. Christiansen C, Thomsen C, Rasmussen O, et al. Wine for type 2 diabetic patients? Diabet Med 1993; 10: 958-961.
100. Koivisto VA, Tulokas S, Toivonen M, et al. Alcohol with a meal has no adverse effect on postprandial glucose homeostasis in diabetic patients. Diabetes Care 1993; 16: 1612-1614.
101. Rimm E, Klatsky A, Grobbee D, Stampfer MJ. Review of moderate alcohol consumption and reduced risk of coronary heart disease: is the effect due to beer, wine or spirits? BMJ 1996; 312: 731-736.
102. Das DK, Sato M, Ray PS, et al. Cardioprotection of red wine: role of polyphenolic antioxidants. Drugs Exp Clin Res 1999; 25: 115-120.
103. Burge MR, Zeise TM, Sobhy TA, et al. Low-dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulphonylurea-induced low blood glucose. Diabetes Care 1999; 22: 2037-2043.
104. Al-Delaimy WK, Manson JE, Solomon CG, et al. Smoking and risk of coronary heart disease among women with type 2 diabetes. Arch Intern Med 2002; 155: 387-393.
105. Al-Delaimy WK, Willett WC, Manson JE, et al. Smoking and mortality among women with type 2 diabetes. Diabetes Care 2001; 24: 2043-2048.
106. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetes with coronary heart disease. Diabetes Care 1997; 20: 614-620.
107. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
108. UK Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complication in type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
109. Atta-ar Rahman, Zaman K. Medicinal Plants with hypoglycaemic activity. J Ethnopharmacol 1989; 26: 1-55.
110. Akhtar MS. Trial of Momordica charantia Linn (Karela) powder in patients with maturity-onset diabetes. J Pak Med Assoc 1982; 32: 106-107.
111. Karunanayake EH, Jeevathayaparan S, Tennekoon KH. Effect of Momordica charantia fruit juice on streptozotocin-induced diabetes in rats. J Ethnopharmacol 1990; 30: 199-204.
112. Rao BK, Kesavulu MM, Apparao C. Antihyperglycaemia activity of Momordica cymbalaria in alloxan diabetic rats. J Ethnopharmacol 2001; 78: 67-71.
113. Akhtar MS, Athar MA, Yaqub M. Effect of Momordica charantia on blood glucose level of normal and alloxan-diabetic rabbits. Plant Medica 1981; 42: 205-212.
114. Sarkar S, Pranava M, Marita R. Demonstration of the hypoglycaemic action of Momordica charantia in a validated animal model of diabetes. Pharmacol Res 1996; 33: 1-4.
115. Leatherdale BA, Panesar RK, Singh G, et al. Improvement in glucose tolerance due to Momordica charantia (Karela). Br Med J (Clin Res ED) 1981; 282; 1823-1824.
116. Kedar P, Chakrabarti CH. Effects of bittergourd (Momordica charantia) seed and glibenclamide in streptozotocin-induced diabetes mellitus. Indian J Exp Biol 1982; 20: 232-235.
117. Shibib BA, Khan LA, Rahman R. Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose 6 phosphatase and fructose 1,6 biphosphatase and elevation of both liver and red cell shunt enzyme glucose 6 phosphatase dehydrogenase. Biochem J 1993; 292: 267-270.
118. Jeevathayaparan S, Tennekoon KH, Karunanayake EH. A comparative study of the oral hypoglycaemic effect of Momordica charantia fruit juice and tolbutamide in streptozotocin-induced graded diabetes in the rat. In J Diabetes 1995; 3: 99-108.
119. Raza H, Ahmed I, John A, Sharma AK. Modulation of xenobiotic metabolism and oxidative stress in chronic streptozotocin-induced diabetic rats fed with Momordica charantia fruit extract. J Biochem Mol Toxicol 2000; 14: 131-139.
120. Singh A, Singh SP, Bamazai R. Postnatal efficacy of Momordica charantia peel, pulp, seed and whole fruit extract in the detoxification pathway of suckling neonates and lactating mice. Cancer Lett 1998; 122: 121-126.
121. Karasu C. Dewhurst M, Stevens EJ, Tomlinson DR. Effects of anti-oxidant treatment on sciatic nerve dysfunction in streptozotocin-diabetic rats; comparison with essential fatty acids. Diabetologia 1995; 38: 129-134.
122. Owens DR, Zinman B, Bolli GB. Insulins today and beyond. Lancet 2001; 358: 739-746.
123. Bolli GB. Hypoglycaemia unawareness. Diabetes Metab 1997; 23 (suppl 3): 29-35.
124. Bolli GB. How to ameliorate the problem of hypoglycaemia in intensive as well as non-intensive treatment of type 1 diabetes mellitus. Diabetes Care 1999; 22 (suppl 2): B43-B52.
125. Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
126. Ciofeta M, Lalli C, Del Sindaco P, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type I diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22: 795-800.
127. Binder C, Lauritzen T, Faber O, Pramming S. Insulin pharmacokinetics. Diabetes Care 1984; 7: 188-199.
128. Bethel MA, Feinglos MN. Insulin analogues: new therapies for type2 diabetes mellitus (review). Curr Diab Rep 2002; 2: 403-408.
129. Dimitriadis GD, and Gerich JE. Importance of timing of preprandial subcutaneous insulin administration in the management of diabetes mellitus. Diabetes Care 1983; 6: 374-377.
130. Bolli GB, Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42: 1151-1167.
131. th Ed., Chapter 61, pp1679-1714, 2001. Edition: McGraw Hills Medical Publishing Division, USA.
132. Lepore M, Pampanelli S, Fanelli CG, et al. Pharmacokinetics and pharmacodynamics of the long-acting human insulin analogue glargine, NPH insulin, and ultralente human insulin injected subcutaneously, and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49: 2142-2148.
133. Riddle MC. New tactics for type 2 diabetes: regimens based on intermediate-acting insulin taken at bedtime. Lancet 1985; 1: 192-195.
134. Davis SN, Thompson CJ, Brown MD, et al. A comparison of the pharmacokinetics and metabolic effects of human regular and NPH insulin mixtures. Diabetes Res Clin Pract 1991; 13: 107-117.
135. Colagiuri S, Villalobos S. Assessing effect of mixed insulins by glucose-clamp technique in subjects with diabetes mellitus. Diabetes Care 1986; 9: 579-586.
136. Dreyer M, Pein M, Schmidt C, et al. Comparison of the pharmacokinetics/dynamics of the Gly (A2)-Arg (B31,B32)-human insulin (HOE71GT) with NPH-insulin following subcutaneous injection by using euglycaemic clamp technique. Diabetologia 1994; 37(Suppl): A78.
137. Owens DR, Barnett A, Designer insulins: have they revolutionized insulin therapy? In: Betteridge DJ, ed. Diabetes: Current Perspectives. London: Dunitz, 1999:223-267.
138. Pieber TR, Eugine-Jolchine I, Derobert E. The European Study Group of HOE901 in type 1 diabetes: efficacy and safety of HOE901 versus NPH insulin in patients with type 1 diabetes. Diabetes 2000; 23: 157-162.
139. Mohn A, Strang S, Wernicke-Panteau J, et al. Nocturnal glucose control and free insulin levels in children with type 1 diabetes by use of the long-acting HOE901 as part of a three-injection regimen. Diabetes Care 2000; 23: 557-559.
140. Henry RR, Gumbiner BN, Ditzler T, et al. Intensive conventional insulin therapy for type II Diabetes. Metabolic effects during 6-month outpatient trial. Diabetes Care 1993; 16: 21-31.
141. Kudlacek S, Schernthaner G. The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five-year follow-up study. Horm Metab Res 1992; 24: 478-483.
142. Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
143. Pampanelli S, Porcellati F, Fanelli C, et al. Glycaemic control, awareness of and counter-regulation to hypoglycaemia, in the second decade of intensive treatment of TIDM (abstract). Diabetes 2002; 51 (Suppl 2): A492.
144. Bott S, Bott U, Berger M, Mühlhauser I. Intensified insulin therapy and the risk of hypoglycaemia. Diabetologia 1997; 40: 926-932.
145. Lalli C, Ciofette M, Del Sindaco et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analogue lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22: 468-472.
146. Cryer PE. Iatrogenic hypoglycaemia as a cause of hypoglycaemia-associated autonomic failure in IDDM. Diabetes 2002; 41: 255-260.
147. Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med 1993; 329: 977-986.
148. Yki-Jarvinen H, Ryysy L, Nikkilä K, Tulokas T, Vanamo R, Heikkila M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized trial. Ann Intern Med 1999; 130: 289-396.
149. Kahn CR, Rosenthal AS. Immunolog reaction to insulin: insulin allergy, insulin resistance, and autoimmune insulin syndrome. Diabetes Care 1979; 2: 283-295.
150. nd ed. Lippincott Williams & Wilkins, Philadelphia, 2000.
151. Ribes G, Trimble ER, Blayac JP, et al. Effect of a new hypoglycaemic agent (HB 699) on the in vivo secretion of pancreatic hormones in the dog. Diabetologia 1981; 20: 501-505.
152. Garrino M-G, Meissner H-P, Henquin J-C. The non-sulfonylurea moiety of gliquidone mimics the effects of the parent molecule on pancreatic B-cells. Eur J Pharmacol 1986; 124: 309-316.
153. Levine R. Sulfonylureas: background development of the field. Diabetes Care 1984; 7 (suppl 1): 3-7.
154. Ferner RE, Chaplin S. The relationship between pharmacokinetics and pharmacodynamic effects of oral hypoglycaemic drugs. Clin Pharmacokin 1987; 12: 379-401.
155. rd ed. (Ellenberg M., and Rifkins H., eds.) Medical Examination Publishing, Garden City. N.Y., 1983, pp 591-610.
156. Jönsson A, Rydberg T, Ekberg G, Hallengren B, Melander A. Slow elimination of glyburide in NIDDM subjects. Diabetes Care 1994; 17: 142-145.
157. Asplund K, Wiholm B-E, Lithner F. Glibenclamide associated hypoglycaemia. A report on 57 cases. Diabetologia 1983; 24: 412-417.
158. Paice BJ, Paterson KR, Lawson DH. Undesired effects of sulfonylurea drugs. Adverse Drug React Acute Poisoning Rev 1985; 4: 23-36.
159. Ferner RE, Neil HAW. Sulfonylureas and hypoglycaemia. Br Med J (Clin Res Ed.) 1988; 296: 949-950.
160. Seltzer HS. Drug-induced hypoglycaemia. A review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163-183.
161. Statistics from the Department of Drugs, Uppsala, Sweden: Swedish Board of Health and Welfare, 1985.
162. Berger W, Cardiff F, Pasquel M, Rump A. Die relative Häufigkeit der schweren sulfonylharnstoff-hypoglykämie in den letzten 25 Jahren in der Schweiz. Schweiz Med Wschr 1986; 116: 145-151.
163. McLaughlin SA, Crandall CS, McKinney PE. Octreotide: an antidote for sulfonylurea-induced hypoglycaemia. Ann Emerg Med 2001; 37: 417-418.
164. Nzerue CM, Thomas J, Volcy J, Edeki T. Use of octreotide to treat prolonged sulfonylurea-induced hypoglycaemia in a patient with chronic renal failure. Int J Artif Organs 2003; 26: 86-89.
165. Campbell IW, Howlett HCS. Worldwide experience of metformin as an effective glucose-lowering agent: a metaanalysis. Diabetes Metab Rev 1995; 11: S57.
166. The UKPDS Group. UKPDS, 16: Overview of 6 years' therapy of type 2 diabetes: a progressive disease. Diabetes 1995; 44: 1249-1258.
167. University Group Diabetes Program. A study of the effects of hypoglycaemia agents on vascular complications in patients with adult-onset diabetes. Diabetes 1970; 19 (suppl 2): 789-830.
168. Lee T-M, Chou T-F. Impairment of myocardial protection in type 2 diabetic patients. J Clin Endocrinol Metab 2003; 88: 531-537.
169. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol 1999; 33: 119-124.
170. Scognamiglio R, Avogaro A, Vigili De Kreutzenberg S, et al. Effects of treatment with sulfonylurea drugs or insulin on ischaemia-induced myocardial dysfunction in type 2 diabetes. Diabetes 2002, 51: 808-812.
171. Jollis JG, Simpson RJ, Cascio WE, et al. Relations between sulfonylurea therapy, complications and outcome for elderly patients with acute myocardial infarction. Am Heart J 1999; 138: S376-S380.
172. Klamann A, Sarfert P, Launhardt V, et al. Myocardial infarction in diabetic vs non-diabetic subjects. Survival and infarct size following therapy with sulfonylureas (Glibenclamide). Eur Heart J 2000; 21: 220.
173. Ashcroft FM, Gribble FM. J Diabetes Complications 2000; 14: 192-196.
174. Schafer G. Biguanides. A review of history, pharmacodynamics, and therapy. Diabetes Metab 1983; 9: 148-163.
175. University Group Diabetes Program. A study of the effects of hypoglycaemic agents on vascular complications in patients with adult-onset diabetes, V: Evaluation of phenformin therapy. Diabetes 1975; 24: (suppl 1): 65-184.
176. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin dependent diabetes mellitus. The Multicenter Metformin Study Group. N Eng J Med 1995; 333: 541-549.
177. Bailey CJ. Biguanides and NIDDM. Diabetes Care 1992; 15: 755-772.
178. Hermann LS. Metformin: a review of its pharmacological properties and therapeutic use. Diabetes Metab 1979; 5: 233-245.
179. Clarke BF, Duncan LJP. Biguanide treatment in the management of insulin dependent (maturity-onset) diabetes: clinical experience with metformin. Res Clin Forums 1979; 1: 53-63.
180. Hundal HS, Ramlal T, Reyes R, et al. Cellular mechanism of metformin action involves glucose transporter translocation from an intracellular pool to the plasma membrane in L6 muscle cells. Endocrinology 1992; 131: 1165-1173.
181. Perriello G, Misericordia P, Volpi E, et al. Acute Antihyperglycaemia mechanisms of metformin in NIDDM: evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes 1994; 43: 920-928.
182. Sum CF, Webster JM, Johnson AB, et al. The effect of intravenous metformin on glucose metabolism during hyperglycaemia in type 2 diabetes. Diabet Metab 1992; 9: 61-65.
183. Wu MS, Johnson P, Sheu WH, et al. Effect of metformin on carbohydrate and lipoprotein metabolism in NIDDM patients. Diabetes care 1990; 13: 1-8.
184. DeFronzo RA, Barzilai N, Simonson DC. Metabolism of metformin action in obese and lean non-insulin dependent diabetic subjects. J Clin Endocrinol Metab 1991; 73: 1294-1301.
185. 12 malabsorption induced by metformin. Diabetes Care 2000; 23: 1227-1231.
186. Bailey C, Turner R. Metformin. N Eng J Med 1996; 334: 574-579.
187. Lalau J, Lacroix C, Compagnon P, de Cagny B, et al. Role of metformin accumulation in metformin-associated lactic acidosis. Diabetes Care 1995; 18: 779-784.
188. Lalau JD, Westeel PF, Debussche X, et al. Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated with metformin. Intensive Care Med 1987; 13: 383-387.
189. Campbell I. Metformin and glibenclamide: comparative risks. BMJ 1984; 289: 289.
190. Rubin CJ, Soufer J, Pieters A, Fiedorek FT. Glipizide/metformin tablets as first-line treatment in type 2 diabetes: efficacy, safety, and tolerability. Diabetes 2002; 51 (suppl 2): A113.
191. Bell DSH, Mayo MS. Outcome of metformin - facilitated reinitiation of oral diabetic therapy in insulin-treated patients with non-insulin-dependent diabetes mellitus. Endocr Pract 1997; 3: 73-76.
192. Jones TA, Sautter M, Van Gaal IF, Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 1630179.
193. UK Prospective Diabetic Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998:352: 854-865.
194. Papoushek C. The "glitazones": Rosiglitazone and pioglitazone. [Review]. J Obstet Gynaecol 2003; 25: 812-815.
195. Bae MA, Rhee H, Song BJ. Troglitazone but not rosiglitazone induces G1 cell arrest and apoptosis in human and rat hepatoma cell lines. Toxicol Lett 2003; 139: 67-75.
196. Lemberger T, Desvergne B, Wahli W. Peroxisome-proliferator-active receptors: a nuclear receptor signaling pathway in lipid physiology. Ann Rev Cell Dev Biol 1996; 12: 335-363.
197. Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-688.
198. Matsuda J, Hosoda K, Itoh H, et al. Increased adipose expression of the uncoupling protein-3 gene by thiazolidinediones in Wistar rats and in cultured adipocytes. Diabetes 1998; 47: 1809-1814.
199. Park KS, Ciaraldi TP, Carter LA, et al. Troglitazone regulation of glucose metabolism in human skeletal muscle cultures from obese type 2 diabetic subjects. J Clin Endocrinol Metab 1998; 83: 1636-1643.
200. Miyazaki Y, Glass L, Triplitt C, et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia 2001; 44: 2210-2219.
201. Aronoff S, Rosenblatt S, Braithewaite S, et al. Pioglitazone hydrochloride monotherapy improves glycaemic control in the treatment of patients with type 2 diabetes: a 6-monthrandomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 2000; 23: 1605-1611.
202. Idris I, Gray S, Donnelly R. Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability. Diabetologia 2003: 46: 288-290.
203. nd, Gozansky WS, Ruscin JM. Possible heart failure exacerbation associated with rosiglitazone: a case report and literature review. [Review]. Pharmacother 2003; 23: 945-954.
204. Dhawan M, Agrawal R, Ravi J, et al. Rosiglitazone-induced granulomatous hepatitis. J Clin Gastroenterol 2002; 34: 582-584.
205. Hu S, Wang S, Fanelli B, et al. Pancreatic beta-cell K (ATP) channel activity and membrane-binding studies with nateglinide: a comparison with sulfonylureas and repaglinide. J Pharmacol Exp Ther 2000; 293: 444-452.
206. Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct process, diabetes 1998; 47: 345-451.
207. Wolffenbuttel BH, Graal MB. New treatments for type 2 diabetes mellitus. Postgrad Med J 1996; 72: 657-662.
208. Gribble FM, Manley SE, Levy JC. Randomized dose ranging study of the reduction of fasting and postprandial glucose in type 2 diabetes by nateglinide (a-4166). Diabetes Care 2001; 24: 1221-1225.
209. Moses R, Siobodniuk R, Boyages S, et al. Effect of repaglinide addition to metformin monotherapy on glycaemic control in patients with type 2 diabetes. Diabetes Care 1999; 22: 119-124.
210. Hirschberg Y, Karara AH, Pietri AO, McLeod JF. Improved control of mealtime glucose excursion with coadministration of nateglinide and metformin. Diabetes Care 2000; 23: 349-353.
211. Bischoff H. The mechanism of a-glucosidase inhibition in the management of diabetes. Clin Invest Med 1995; 18:303-311.
212. Reabasa-Lhoret R, Chiasson JL. Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance. Drug Aging 1998; 13: 131-143.
213. Kageyama S, Kakamichi N, Sekino H, Nakano S. Comparison of the effects of acarbose and voglibose in healthy subjects. Clin Ther 1997; 19: 720-729.
214. Rosak C, Nitzsche G, Konig P, Hoffmann U. The effect of the timing and the administration of acarbose on postprandial hyperglycaemia. Diabet Med 1995; 12: 979-984.
215. Lebovitz H. Alpha-glucosidase inhibitors as agents in the treatment of diabetes. Diabet Rev 1998; 6: 132-145.
216. Bressler R, Johnson D. New pharmacological approaches to therapy of NIDDM. Diabetes Care 1992; 15: 792-805.
217. Coniff RF, Shapiro JA, Seaton TB, Bray GA. Multicenter placebo-controlled trial comparing acarbose (Bay g5421) with placebo, tolbutamide and tolbutamide-plus-acarbose in non-insulin-dependent diabetes mellitus. Am J Med 1995; 98: 443-451.
218. Hoffman J, Spengler M. Efficacy of 24-week monotherapy with acarbose, glibenclamide, or placebo in NIDDM patients. The Essen Study, Diabetes Care 1994; 17: 561-566.
219. Willms B, Ruge D. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulfonylureas: a randomized-placebo-controlled study. Diabet Med 1999; 16: 755-761.
220. Wolffenbuttel BH, Landgraf R, for the Dutch and German Repaglinide Study Group. A 1-year Multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 1999; 22: 463-467.
221. Holman RR, Cull CA, Turner RC. A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycaemic control over 3 years (UK Prospective Diabetes Study 44). Diabetes Care 1999; 22: 960-964.
222. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47: 159-169.
223. Filipsson K, Kvist-Reimer M, Ahren B. The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function. Diabetes 2001; 50: 1959-1969.
224. Bailey CJ. New pharmacological approaches to glycaemic control. Diabetes Rev 1999; 7: 94-113.
225. Anderson RA, Cheng N, Bryden NA, et al. Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes. Diabetes 1997, 46: 12786-1791.
226. Ohly P, Dohle C, Abel J, Seissler J, Gleichmann H. Zinc sulphate induces metallothionein in pancreatic islets of mice and protects against diabetes induced by multiple low doses of streptozotocin. Diabetologia 2000; 43: 1020-1030.
227. Tsiani E, Fantus IG. Vanadium compounds. Biological actions and potential as pharmacological agents. Trends Endocrinol Metab 1997; 8: 51-58.